Beneficial effects of curcumin and DHA on human health: Relevance to chronic diseases of aging

Phytochemicals and Human Health: Pharmacological and Molecular Aspects - A Tribute to Late Professor Bimal Kumar Bachhawat

Volumn , Issue , 2011, Pages 369-387

  Frautschy, Sally A ^a   Cole, Greg M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Veteran's Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891997024     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (108)

1. Wang YY, Pan MH, Cheng AL, et al. Stability of curcumin in buffer solutions and characterization of its degradation products. J. Pharm. Biomed. Anal. 1997; 15: 1867-1876.
2. Ireson CR, Jones DJ, Orr S, et al. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 105-111.
3. Begum AN, Jones MR, Lim GP, et al. Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease. JPET 2008; 326: 196-208.
4. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 2001; 7: 1894-1900.
5. Liu A, Lou H, Zhao L, Fan P. Validated LC/MS/MS assay for curcumin and tetrahydrocurcumin in rat plasma and application to pharmacokinetic study of phospholipid complex of curcumin. J. Pharm. Biomed. Anal. 2006; 40: 720-727.
6. Jiang J, Wang W, Sun YJ, et al. Neuroprotective effect of curcumin on focal cerebral ischemic rats by preventing blood-brain barrier damage. Eur. J. Pharmacol. 2007; 561: 54-62.
7. Heath DD, Pruitt MA, Brenner DE, et al. Tetrahydrocurcumin in plasma and urine: Quantitation by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2005; 824: 206-212.
8. Heath DD, Pruitt MA, Brenner DE, Rock CL. Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2003; 783: 287-295.
9. Marczylo TH, Steward WP, Gescher AJ. Rapid analysis of curcumin and curcumin metabolites in rat biomatrices using a novel ultraperformance liquid chromatography (UPLC) method. J. Agric. Food Chem. 2009; 57: 797-803.
10. Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998; 64: 353-356.
11. Maiti K, Mukherjee K, Gantait A, et al. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 2007; 330: 155-163.
12. Marczylo TH, Verschoyle RD, Cooke DN, et al. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chem-other. Pharmacol. 2007; 60: 171-177.
13. Takahashi M, Uechi S, Takara K, et al. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J. Agric. Food Chem. 2009; 57: 9141-9146.
14. Gota VS, Maru GB, Soni TG, et al. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J. Agric. Food Chem. 2010; 58: 2095-2099.
15. Lee CK, Klopp RG, Weindruch R, Prolla TA. Gene expression profile of aging and its retardation by caloric restriction. Science. 1999; 285: 1390-1393.
16. Lee CK, Weindruch R, Prolla TA. Gene-expression profile of the ageing brain in mice. Nat. Genet. 2000; 25: 294-297.
17. Barger JL, Kayo T, Vann JM, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One. 2008; 3: e2264.
18. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444: 337-342.
19. Pearson KJ, Baur JA, Lewis KN, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008; 8: 157-168.
20. Kitani K, Yokozawa T, Osawa T. Interventions in aging and age-associated pathologies by means of nutritional approaches. Ann. N. Y. Acad. Sci. 2004; 1019: 424-426.
21. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv. Exp. Med. Biol. 2007; 595: 1-75.
22. Cole GM, Teter B, Frautschy SA. Neuroprotective effects of curcumin. Adv. Exp. Med. Biol. 2007; 595: 197-212.
23. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J. Biochem. Cell Biol. 2009; 41: 40-59.
24. Kato K, Ito H, Kamei K, Iwamoto I. Stimulation of the stress-induced expression of stress proteins by curcumin in cultured cells and in rat tissues in vivo. Cell Stress Chaperones. 1998; 3: 152-160.
25. Balogun E, Hoque M, Gong P, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem. J. 2003; 371: 887-895.
26. Yang C, Zhang X, Fan H, Liu Y. Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 2009; 1282: 133-141.
27. Weisberg SP, Leibel R, Tortoriello DV. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. Endocrinology. 2008; 149: 3549-3558.
28. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460: 392-395.
29. Beevers CS, Chen L, Liu L, et al. Curcumin disrupts the Mammalian target of rapamycin-raptor complex. Cancer Res. 2009; 69: 1000-1008.
30. Yu S, Shen G, Khor TO, et al. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism. Mol. Cancer Ther. 2008; 7: 2609-2620.
31. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther. 2008; 326: 196-208.
32. Kelloff GJ, Crowell JA, Hawk ET, et al. Strategy and planning for chemopreventive drug development: clinical development plan: curcumin. J. Cell Biochem. Suppl. 1996; 26: 72-85.
33. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23: 363-398.
34. Lao CD, Ruffin MTt, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 2006; 6: 10.
35. Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging. 2001; 22: 993-1005.
36. Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001; 21: 8370-8377.
37. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005; 280: 5892-5901.
38. Garcia-Alloza M, Borrelli LA, Rozkalne A, et al. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 2007; 102: 1095-1104.
39. Cole GM, Yang F, Lim GP, et al. A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimer's Disease. Curr. Med. Chem. Immun., Endoc., and Metab. Agents. 2003; 3: 15-25.
40. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004; 75: 742-750.
41. Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 2009; 29: 9078-9089.
42. Caughey B, Raymond LD, Raymond GJ, et al. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J. Virol. 2003; 77: 5499-5502.
43. Pandey N, Strider J, Nolan WC, et al. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008; 115: 479-489.
44. Narlawar R, Pickhardt M, Leuchtenberger S, et al. Curcumin-Derived Pyrazoles and Isoxazoles: Swiss Army Knives or Blunt Tools for Alzheimer's Disease? Chem. Med. Chem. 2008; 3: 165-172.
45. Ringman JM, Frautschy SA, Cole GM, et al. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer. Res. 2005; 2: 131-136.
46. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism. Relat. Disord. 2009; 15 Suppl 3: S189-194.
47. Mythri RB, Jagatha B, Pradhan N, et al. Mitochondrial complex I inhibition in Parkinson's disease: how can curcumin protect mitochondria? Antioxid. Redox. Signal. 2007; 9: 399-408.
48. Jagatha B, Mythri RB, Vali S, Bharath MM. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic. Biol. Med. 2008; 44: 907-917.
49. Yu S, Zheng W, Xin N, et al. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res. 13: 55-64.
50. Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology. 2008; 16: 96-99.
51. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology. 2007; 69: 1480-1490.
52. Zbarsky V, Datla KP, Parkar S, et al. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic. Res. 2005; 39: 1119-1125.
53. Seugnet L, Galvin JE, Suzuki Y, et al. Persistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease. Sleep. 2009; 32: 984-992.
54. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009; 8: 382-397.
55. Qin L, Wu X, Block ML, et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia. 2007; 55: 453-462.
56. O'Meara ES, Kukull WA, Sheppard L, et al. Head injury and risk of Alzheimer's disease by Apolipoprotein E genotype. American Journal of Epidemiology. 1997; 146: 373-384.
57. Jordan BD, Relkin NR, Ravdin LD, et al. Apolipoprotein E e4 associated with chronic traumatic brain injury in boxing. JAMA. 1997; 278: 136-140.
58. Wu A, Ying Z, Gomez-Pinilla F. Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition. Exp. Neurol. 2006; 197: 309-317.
59. Wu A, Ying Z, Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma. 2004; 21: 1457-1467.
60. Wu A, Ying Z, Gomez-Pinilla F. Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J. Neurotrauma. 2007; 24: 1587-1595.
61. Sharma S, Zhuang Y, Ying Z, et al. Dietary curcumin supplementation counteracts reduction in levels of molecules involved in energy homeostasis after brain trauma. Neuroscience. 2009; 161: 1037-1044.
62. Wakade C, King MD, Laird MD, et al. Curcumin attenuates vascular inflammation and cerebral vasospasm after subarachnoid hemorrhage in mice. Antioxid. Redox. Signal. 2009; 11: 35-45.
63. Laird MD, Sukumari-Ramesh S, Swift AE, et al. Curcumin attenuates cerebral edema following traumatic brain injury in mice: a possible role for aquaporin-4? J. Neurochem. 113: 637-648.
64. Lin MS, Lee YH, Chiu WT, Hung KS. Curcumin Provides Neuroprotection After Spinal Cord Injury. J. Surg. Res. 2009; in press.
65. Thiyagarajan M, Sharma SS. Neuroprotective effect of curcumin in middle cerebral artery occlusion induced focal cerebral ischemia in rats. Life Sci. 2004; 74: 969-985.
66. Zhao J, Zhao Y, Zheng W, et al. Neuroprotective effect of curcumin on transient focal cerebral ischemia in rats. Brain Res. 2008; 1229: 224-232.
67. Shukla PK, Khanna VK, Ali MM, et al. Anti-ischemic effect of curcumin in rat brain. Neurochem. Res. 2008; 33: 1036-1043.
68. Wang Q, Sun AY, Simonyi A, et al. Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J. Neurosci. Res. 2005; 82: 138-148.
69. Dohare P, Garg P, Jain V, et al. Dose dependence and therapeutic window for the neuroprotective effects of curcumin in thromboembolic model of rat. Behav. Brain Res. 2008; 193: 289-297.
70. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J. Immunol. 2002; 168: 6506-6513.
71. Xie L, Li XK, Funeshima-Fuji N, et al. Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int. Immunopharmacol. 2009; 9: 575-581.
72. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr. Pharm. Des. 2009; 15: 2087-2094.
73. Bright JJ. Curcumin and autoimmune disease. Adv. Exp. Med. Biol. 2007; 595: 425-451.
74. Thangapazham RL, Sharma A, Maheshwari RK. Beneficial role of curcumin in skin diseases. Adv. Exp. Med. Biol. 2007; 595: 343-357.
75. Thaloor D, Miller KJ, Gephart J, et al. Systemic administration of the NF-kappab inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am. J. Physiol. 1999; 277: C320-329.
76. Cuthbertson D, Smith K, Babraj J, et al. Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005; 19: 422-424.
77. Peterson JM, Guttridge DC. Skeletal muscle diseases, inflammation, and NF-kappaB signaling: insights and opportunities for therapeutic intervention. Int. Rev. Immunol. 2008; 27: 375-387.
78. Miriyala S, Panchatcharam M, Rengarajulu P. Cardioprotective effects of curcumin. Adv. Exp. Med. Biol. 2007; 595: 359-377.
79. Wongcharoen W, Phrommintikul A. The protective role of curcumin in cardiovascular diseases. Int. J. Cardiol. 2009; 133: 145-151.
80. Nan B, Yang H, Yan S, et al. C-reactive protein decreases expression of thrombomodulin and endothelial protein C receptor in human endothelial cells. Surgery. 2005; 138: 212-222.
81. Yuan HY, Kuang SY, Zheng X, et al. Curcumin inhibits cellular cholesterol accumulation by regulating SREBP-1/caveolin-1 signaling pathway in vascular smooth muscle cells. Acta Pharmacol. Sin. 2008; 29: 555-563.
82. Morimoto T, Sunagawa Y, Kawamura T, et al. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest. 2008; 118: 868-878.
83. Seo KI, Choi MS, Jung UJ, et al. Effect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db mice. Mol. Nutr. Food Res. 2008; 52: 995-1004.
84. Kanitkar M, Gokhale K, Galande S, Bhonde RR. Novel role of curcumin in the prevention of cytokine-induced islet death in vitro and diabetogenesis in vivo. Br. J. Pharmacol. 2008; 155: 702-713.
85. Kanitkar M, Bhonde RR. Curcumin treatment enhances islet recovery by induction of heat shock response proteins, Hsp70 and heme oxygenase-1, during cryopreservation. Life Sci. 2008; 82: 182-189.
86. Feng B, Chen S, Chiu J, et al. Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am. J. Physiol. Endocrinol. Metab. 2008; 294: E1119-1126.
87. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annual. Review of Nutrition. 2010;
88. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. (Lond). 2008; 5: 17.
89. Usharani P, Mateen AA, Naidu MU, et al. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study. Drugs R D. 2008; 9: 243-250.
90. Mori TA, Puddey IB, Burke V, et al. Effect of omega 3 fatty acids on oxidative stress in humans: GC-MS measurement of urinary F2-isoprostane excretion. Redox. Rep. 2000; 5: 45-46.
91. Cole GM, Frautschy SA. DHA May Prevent Age-Related Dementia. J. Nutr. 2010;
92. Cole GM, Ma QL, Frautschy SA. Omega-3 fatty acids and dementia. Prostaglandins. Leukot. Essent. Fatty Acids. 2009; 81: 213-221.
93. Heller AR, Rössler S, Litz RJ, et al. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med. 2006; 2006:972-9.
94. Horrocks LA, Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999; 40: 211-225.
95. Yurko-Mauro K. Cognitive and Cardiovascular Benefits of Docosahexaenoic Acid in Aging and Cognitive Decline. Curr. Alzheimer. Res. 2010; 7:190-6.
96. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 2006; 63: 1402-1408.
97. Quinn JF, Raman R, Thomas RG, et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA. 2010 304: 1903-11.
98. Cole GM, Frautschy SA. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp. Gerontol. 2007; 42: 10-21.
99. Cleland LG, Caughey GE, James MJ, Proudman SM. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. J. Rheumatol. 2006; 33: 1973-1979.
100. Lee JH, O'Keefe JH, Lavie CJ, et al. Omega3 fatty acids for cardioprotection. Mayo. Clin. Proc. 2008; 83: 324-332.
101. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008; 197: 12-24.
102. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA. 2006; 296: 1885-1899.
103. Hillyard SL, German JB. Quantitative lipid analysis and life span of the fat-3 mutant of Caenorhabditis elegans. J. Agric. Food Chem. 2009; 57: 3389-3396.
104. Tsitouras PD, Gucciardo F, Salbe AD, et al. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults. Horm. Metab. Res. 2008; 40: 199-205.
105. Takeuchi H, Sekine S, Noguchi O, et al. Effect of life-long dietary n-6/n-3 fatty acid ratio on life span, serum lipids and serum glucose in Wistar rats. J. Nutr. Sci. Vitaminol. (Tokyo). 2009; 55: 394-399.
106. Calon F, Lim GP, Yang F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron. 2004; 43: 633-645.
107. Shinto L, Quinn J, Montine T, et al. Omega-3 Fatty Acids and Lipoic Acid in Alzheimer's Disease. Neurology. 2008; 70: A393.
108. Scheltens P, Kamphuis PJ, Verhey FR, et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement. 2010; 6: 1-10 e11.